FMOC Pre-Meeting Survey: June 17 Steering Committee - Prostate Cancer Biomarker Testing

Question Title

1. Enter your name

Question Title

2. Within your organization, what are the barriers to prostate cancer biomarker/genetic testing? (select all that apply)

Workflow (eg, ordering tests, tissue procurement, turnaround time for and/or interpretation of test results)

Technology limitations (eg, electronic health record [EHR] challenges)

Coverage and reimbursement

Provider awareness/education

Genetic counselor availability

Other (please specify)

Question Title

3. Please rank the impact the following barriers have on prostate cancer biomarker/genetic testing policy development. (1= lowest impact, 5 = highest impact)

Question Title

4. At your organization, who is the ultimate decision-maker for the prostate cancer genetic/biomarker testing program and policies?

Pathology department

Formulary/Pharmacy & Therapeutics Committee

Health care provider

Molecular tumor board

Other (please specify)

Not applicable

Question Title

5. If you selected Health care provider in question 4 above, please select the type below.

Physicians

Pharmacists

Genetic counselors

Nurse navigators

Other (please specify)

Question Title

6. If your system is not 100% concordant with published guidelines, at what level is the decision to follow published guidelines made?

Health system level

Satellite system level

Clinic level (eg, urology clinic, medical oncology clinic, etc.)

Disease state specialists’ level (eg, prostate cancer specialist)

Individual health care provider level

Mixture of the above

Other (please specify)

Question Title

7. Which of the following biomarker testing partnership or collaborator types do you use or anticipate using in the future? (select all that apply)

EHR vendors

Laboratories/diagnostic companies that perform genetic testing

Drug manufacturers

Specialty pharmacies

Other (please specify)

Not applicable

Question Title

8. For clinical pathways that incorporate biomarker testing for prostate cancer, which of the following testing criteria are specified? (select all that apply)

Tissue source to be tested

Patient eligibility per guidelines

Test category (ie, germline or somatic or both)

Genetic testing vendor/vendor type (eg, organization’s preferred vendor, vendor that offers next generation sequencing)

Other (please specify)

Not applicable

Question Title

9. Which of the following resources would help your organization to improve guideline concordant care with prostate cancer biomarker testing? (select all that apply)

Published guidelines

Drug label

EHR clinical decision support tool

Payer guidelines/coverage criteria

Patient education

Other (please specify)

None of the above

Question Title

10. Please rank the following resources for level of importance with assisting your organization to better align on a prostate cancer pathway/coverage policy. (1 = least important, 4 = most important)

FMOC Pre-Meeting Survey: June 17 Steering Committee - Prostate Cancer Biomarker Testing

Question Title

* 1. Enter your name

Question Title

* 2. Within your organization, what are the barriers to prostate cancer biomarker/genetic testing? (select all that apply)

Question Title

* 3. Please rank the impact the following barriers have on prostate cancer biomarker/genetic testing policy development. (1= lowest impact, 5 = highest impact)

Question Title

* 4. At your organization, who is the ultimate decision-maker for the prostate cancer genetic/biomarker testing program and policies?

Question Title

* 5. If you selected Health care provider in question 4 above, please select the type below.

Question Title

* 6. If your system is not 100% concordant with published guidelines, at what level is the decision to follow published guidelines made?

Question Title

* 7. Which of the following biomarker testing partnership or collaborator types do you use or anticipate using in the future? (select all that apply)

Question Title

* 8. For clinical pathways that incorporate biomarker testing for prostate cancer, which of the following testing criteria are specified? (select all that apply)

Question Title

* 9. Which of the following resources would help your organization to improve guideline concordant care with prostate cancer biomarker testing? (select all that apply)

Question Title

* 10. Please rank the following resources for level of importance with assisting your organization to better align on a prostate cancer pathway/coverage policy. (1 = least important, 4 = most important)

1. Enter your name

2. Within your organization, what are the barriers to prostate cancer biomarker/genetic testing? (select all that apply)

3. Please rank the impact the following barriers have on prostate cancer biomarker/genetic testing policy development. (1= lowest impact, 5 = highest impact)

4. At your organization, who is the ultimate decision-maker for the prostate cancer genetic/biomarker testing program and policies?

5. If you selected Health care provider in question 4 above, please select the type below.

6. If your system is not 100% concordant with published guidelines, at what level is the decision to follow published guidelines made?

7. Which of the following biomarker testing partnership or collaborator types do you use or anticipate using in the future? (select all that apply)

8. For clinical pathways that incorporate biomarker testing for prostate cancer, which of the following testing criteria are specified? (select all that apply)

9. Which of the following resources would help your organization to improve guideline concordant care with prostate cancer biomarker testing? (select all that apply)

10. Please rank the following resources for level of importance with assisting your organization to better align on a prostate cancer pathway/coverage policy. (1 = least important, 4 = most important)